Cinclus Pharma Holding AB
Quick facts
Phase 3 pipeline
- Lansoprazole - Marketed approved dose · Gastroenterology
Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. - Linaprazan glurate - High dose · Gastroenterology
Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion. - Linaprazan glurate - Low dose · Gastroenterology
Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Cinclus Pharma Holding AB
What is Cinclus Pharma Holding AB's pipeline?
Cinclus Pharma Holding AB has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Lansoprazole - Marketed approved dose, Linaprazan glurate - High dose, Linaprazan glurate - Low dose.
Related
- Sector hub: All tracked pharma companies